← Bangkok Dusit Medical Services overview

Bangkok Dusit Medical Services vs HCA Healthcare: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bangkok Dusit Medical Services Public Company Limited (BDMS.BK)

Q3 2026
▲3▼1

BDMS Q3 rebound: revenue up, profit record forecast, risks remain

  • Revenue rebound and occupancy recovery After a weak Q2, July revenue jumped 8% and occupancy rebounded to 65%, with August revenue up 10%. Analysts called Q2 the year's low and maintained Buy ratings.

    This is the key new positive development that drove the stock in Q3.

  • Record Q3 profit forecast and higher targets Brokers forecast a record Q3 profit of 4.5–4.6 billion baht and raised price targets to as high as 25 baht, citing medical tourism and an 18.8% September rebound in Middle East revenue.

    This shows analyst optimism and upward revisions that likely supported the stock price.

  • WellEra wellness project adds long-term growth The WellEra wellness project is expected to contribute to long-term growth, expanding BDMS's service offerings and tapping into the growing wellness tourism market.

    This is a new strategic initiative that could drive future growth and investor interest.

  • Bangkok floods threaten Q3 profit Bangkok floods could cut Q3 profit by 0.5–1.5%, posing a risk to the strong recovery and potentially dampening investor sentiment.

    This is a key risk factor that could negatively impact Q3 results and stock performance.

September 2026
▲3▼1

BDMS Q3 profit set to hit record on strong August revenue

  • Record Q3 profit forecast Brokers expect BDMS to report a record quarterly profit of 4.5–4.6 billion baht for Q3 2026, up sharply from Q2, as August revenue growth reached 10%, the first double-digit gain since 2024.

    This is the central new development driving positive sentiment for the period.

  • Broker upgrades and higher targets Multiple brokerages raised their price targets for BDMS, with some going up to 25 baht, and maintained buy ratings, citing the weak baht, medical tourism, and a recovering Middle East patient segment.

    Analyst upgrades directly influence investor expectations and stock price.

  • Middle East patient recovery Middle Eastern patient revenue rose 18.8% in September, signaling a rebound from earlier weakness caused by regional unrest, which had previously dragged down international income.

    This shows a key international segment is recovering, supporting future growth.

  • Flood risk to Q3 profit Bangkok floods could reduce Q3 profit by 0.5–1.5%, posing a short-term risk to earnings, though the impact is expected to be limited.

    This is a new risk factor that could dampen the positive outlook.

Latest
▲4

BDMS Set for Record Q3 Profit as Brokers Turn Bullish

  • Record Q3 profit expected Bualuang Securities expects BDMS to report a record Q3 2026 core profit of 4.6 billion baht, up 7% year-on-year and 42% quarter-on-quarter, driven by flu and COVID season, recovering foreign patients, and a low base from weak Cambodia business. This directly boosts earnings expectations and supports the share price.

    This is the most direct and material new catalyst for BDMS's earnings outlook.

  • Brokers raise targets and recommend buying Multiple brokerages issued buy ratings and target prices for BDMS this period: KKPS at 23.50 baht, Asia Plus at 25.00 baht, LHSEC at 25.00 baht, and Bualuang at 23.00 baht. These recommendations reflect growing confidence and can attract investors, pushing the price up.

    Broker upgrades and buy calls are a key driver of investor sentiment and demand for the stock.

  • Middle East patient recovery Middle Eastern tourist numbers rose 18.8% year-on-year in September, with complex cases returning. BDMS derives about 4% of revenue from this group, but higher-margin cases support profit recovery. This helps offset earlier weakness from Middle East unrest.

    The recovery in foreign patients is a significant revenue and margin driver for BDMS.

  • Flood impact limited, demand rebound expected Brokerages estimate the Bangkok floods will have a minimal impact on BDMS, with only 0.5-1.5% of Q3 profit affected. Postponed checkups are expected to return in October, supporting Q4 revenue. This reassures investors that the flood is not a major threat.

    It removes a potential negative overhang and points to a near-term rebound.

▲4

BDMS Rides Record Q3 Profit Forecasts and Weak-Baht Tailwind

  • Brokers hike targets on record Q3 profit TISCO raised its BDMS target to 24.50 baht and lifted 2026-2028 earnings forecasts by 7-9%. Krungsri and KGI both see a record third-quarter profit near 4.5 billion baht, up sharply from Q2, as revenue growth accelerates to around 9-10%.

    This is the core new reason the stock is moving: analysts now expect a record profit rebound, not just a bottom.

  • August revenue growth hits 10%, first double-digit since 2024 August hospital revenue grew 10% year-on-year, up from 8% in July, the first double-digit growth since early 2024. Thai patients, insured patients and a recovering Middle East segment are all contributing, easing the drag from Cambodia and Middle East unrest seen in Q2.

    It shows the operational recovery is real and broadening, which underpins the higher profit forecasts.

  • Weak baht and Fed hike make BDMS a defensive pick The baht has weakened past 33 per dollar and the Fed raised rates again, pushing bond yields to multi-year highs. Brokers including Pie, KSS and InnovestX name BDMS among value or defensive stocks that benefit from medical tourism and steady domestic revenue.

    It explains the macro force steering new money into BDMS even as the broad market weakens.

  • Wellness push adds long-term growth story KGI notes Thailand's wellness market is worth $42.7 billion and growing 7-10% a year. BDMS aims to lift wellness to 20% of revenue by 2035 from 12% in 2025, with the WellEra project valued at 26.5 billion baht as a long-term driver.

    It gives a structural reason beyond the current profit cycle for why investors are positive on BDMS.

August 2026
▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

HCA Healthcare, Inc. (HCA)

Q3 2026
▼3▲1

HCA Cuts Guidance on ACA Coverage Losses, Nursing Shortage

  • Guidance Cut on ACA Coverage Losses HCA cut 2026 profit guidance to $28.70–$30.50 per share, citing a $400 million quarterly hit as patients lost ACA exchange coverage and became uninsured. Exchange admissions fell 15% while uninsured admissions rose 15%.

    This is the main new negative event that drove the stock down about 7%.

  • Worsening Nursing Shortage and Cost Cuts HCA faces a worsening nursing shortage (28% to 39%) and responded with layoffs and a hospital sale. Surgeries declined 2.3–3.4% and operating cash flow dropped 45%.

    This is a new operational challenge that adds to cost pressures and affects patient volumes.

  • Strong Q2 Results and AI Edge Q2 beat estimates ($7.59/share, $20.23 billion revenue), admissions grew 2.7%, EPS rose 11%, and UBS views HCA's AI investments as a durable edge.

    This is a new positive counterweight showing underlying business strength and future potential.

  • Securities Fraud Investigation Law firms are investigating possible securities fraud after the guidance cut, though no wrongdoing is proven. This adds uncertainty and potential legal costs.

    This is a new risk factor that could weigh on investor sentiment.

August 2026
▼4

HCA's profit outlook cut as payer mix worsens; lawsuits follow

  • Guidance cut on payer mix, stock drops 7% HCA sharply lowered its full-2026 profit guidance on July 14, saying a worse mix of who pays for care cut revenue by about $400 million in the second quarter. The stock fell 6.95% that day. This is the core reason HCA is moving: less profit expected.

    The guidance cut is the single biggest new force behind HCA's price move this period.

  • Law firms probe possible securities fraud After the guidance cut, law firms Pomerantz and Bragar Eagel & Squire said they are investigating whether HCA misled investors about its prior disclosures. Investigations can lead to lawsuits, legal costs and further pressure on the stock, though no wrongdoing has been proven.

    New legal investigations add a fresh overhang on top of the guidance cut.

  • ACA subsidy lapse worsens payer mix, layoffs follow Expiring Affordable Care Act subsidies pushed patients toward cheaper or no insurance, hurting HCA's revenue per patient. HCA responded with targeted layoffs and at least one hospital sale. Policy-driven payment changes can hit hospital profits fast, and this weakens HCA's earlier upbeat long-term growth story.

    Explains the policy cause behind the guidance reset and the company's cost-cutting response.

  • Fewer exchange and surgery patients squeeze margins Exchange-related admissions fell 15% while uninsured admissions rose 15%, and inpatient and outpatient surgeries dropped 2.3% and 3.4% on weaker elective demand. Overall admissions still grew 2.7% and profit per share rose 11%, but the richer-paying business is shrinking, which pressures future earnings.

    Gives the latest hard numbers showing the payer-mix problem is ongoing, not just a one-time guidance issue.

Latest
▼4

HCA's profit outlook cut as payer mix worsens; lawsuits follow

  • Guidance cut on payer mix, stock drops 7% HCA sharply lowered its full-2026 profit guidance on July 14, saying a worse mix of who pays for care cut revenue by about $400 million in the second quarter. The stock fell 6.95% that day. This is the core reason HCA is moving: less profit expected.

    The guidance cut is the single biggest new force behind HCA's price move this period.

  • Law firms probe possible securities fraud After the guidance cut, law firms Pomerantz and Bragar Eagel & Squire said they are investigating whether HCA misled investors about its prior disclosures. Investigations can lead to lawsuits, legal costs and further pressure on the stock, though no wrongdoing has been proven.

    New legal investigations add a fresh overhang on top of the guidance cut.

  • ACA subsidy lapse worsens payer mix, layoffs follow Expiring Affordable Care Act subsidies pushed patients toward cheaper or no insurance, hurting HCA's revenue per patient. HCA responded with targeted layoffs and at least one hospital sale. Policy-driven payment changes can hit hospital profits fast, and this weakens HCA's earlier upbeat long-term growth story.

    Explains the policy cause behind the guidance reset and the company's cost-cutting response.

  • Fewer exchange and surgery patients squeeze margins Exchange-related admissions fell 15% while uninsured admissions rose 15%, and inpatient and outpatient surgeries dropped 2.3% and 3.4% on weaker elective demand. Overall admissions still grew 2.7% and profit per share rose 11%, but the richer-paying business is shrinking, which pressures future earnings.

    Gives the latest hard numbers showing the payer-mix problem is ongoing, not just a one-time guidance issue.

July 2026
▼3▲1

HCA cuts guidance on coverage losses, but Q2 beat lifts shares

  • Guidance cut on coverage losses HCA cut its 2026 profit guidance to $28.70–$30.50 per share, citing a $400 million hit from patients losing exchange coverage—now expected to reach $1–1.2 billion as most became uninsured.

    This is the main negative driver of the period, directly reducing expected earnings.

  • Worsening nursing shortage and legal probes A worsening nursing shortage (28% to 39%) raises labor-cost concerns, and three law firms are investigating whether HCA misled investors about its payer mix.

    These add cost pressure and legal uncertainty, weighing on investor sentiment.

  • Volume and cash flow decline Surgeries fell 2.3–3.4% and operating cash flow dropped 45%, signaling weaker demand and cash generation.

    These operational metrics show underlying business deterioration.

  • Q2 earnings beat and AI edge Q2 earnings beat estimates ($7.59/share, $20.23 billion revenue), lifting shares over 5%. UBS sees HCA's AI investments in denials and staffing as a durable edge over insurers, and positive NEJM CRISPR gene-therapy results strengthen its advanced-care reputation, though near-term earnings impact is limited.

    This positive news offset the negative guidance and drove the stock higher.

▼2▲1

HCA hit by uninsured surge, law firm probes; Q2 beat lifts shares

  • Law firm investigations into HCA Three law firms opened investigations into whether HCA misled investors about its payer mix before cutting guidance. No lawsuit has been filed, but the probes add legal uncertainty and can weigh on the stock by raising the risk of future costs and management distraction.

    New legal risk directly tied to HCA's guidance cut, affecting investor confidence.

  • Q2 earnings beat estimates HCA reported second-quarter earnings of $7.59 per share, beating estimates by $0.09, on revenue of $20.23 billion, which topped expectations by $490 million. Same-facility admissions rose 2.5%. The beat shows the core business is still growing, which pushed the stock up over 5% on the day.

    New positive earnings surprise that lifted the stock, showing underlying demand strength.

  • Exchange headwind larger than expected HCA now expects a $1 billion to $1.2 billion hit from patients losing health insurance exchange coverage, as nearly all became uninsured rather than switching plans. This reduces revenue per visit and forced a cut to full-year profit guidance, pressuring the stock.

    New detail on the size and cause of the guidance cut, a key negative driver.

  • Surgery declines and cash flow drop Inpatient and outpatient surgeries fell 2.3% and 3.4%, partly from fewer elective procedures, and operating cash flow dropped 45% to $2.3 billion. Weaker surgery volumes and cash generation are warning signs, though HCA still approved over $7 billion in capital spending and bought back $2.1 billion of stock.

    New operational weakness that offsets the earnings beat and could limit future growth.

▲2▼2

HCA cuts 2026 profit outlook as uninsured patients rise; AI and gene therapy offer long-term support

  • HCA slashes 2026 profit guidance on payer mix shift HCA cut its full-year 2026 earnings guidance to $28.70–$30.50 per share from $29.10–$31.50, citing a $400 million hit from patients losing health insurance exchange coverage. More uninsured patients mean less revenue per visit, directly reducing profits and pressuring the stock.

    This is the single biggest new event this period and the main reason HCA's stock fell.

  • Nursing shortage worsens, raising labor cost fears A reported jump in the nursing shortage rate from 28% to 39% signals higher labor costs ahead for hospitals. HCA already spends heavily on staffing, so a tighter nurse supply could squeeze margins further and adds to the negative sentiment from the profit warning.

    This is a new, separate pressure on HCA's costs that reinforces the negative outlook.

  • UBS: hospitals may keep AI gains better than insurers UBS analysts argue HCA's use of AI for claim denials and nurse staffing (via a Palantir-built platform) could give hospitals a durable edge over insurers, whose AI gains are easily copied. If HCA retains these efficiency savings, it could expand margins over time.

    This is a new analyst view highlighting a potential long-term positive driver for HCA.

  • Gene therapy milestone boosts HCA's advanced care profile HCA researchers published positive NEJM results for a CRISPR therapy in young children with blood disorders, and HCA is expanding access to these treatments. While it won't move near-term earnings, it strengthens HCA's reputation in advanced specialty care and clinical research.

    This is a new development that supports HCA's long-term growth story, even if it's not an immediate financial driver.